Your browser of choice has not been tested for use with Barchart.com. If you have issues, please download one of the browsers listed here.
Get your Portfolio automatically emailed to you up to 4 times a day. FREE 30 Day Trial

Stocks | Futures | Watchlist | More
or

Calliditas Therapeutics Ab ADR (CALT)

Calliditas Therapeutics Ab ADR (CALT)

[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] by (Cboe BZX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
Quote Overview for [[ item.sessionDateDisplayLong ]]
[[ rowChartData.labelLow ]]
[[ rowChartData.lowPriceFormatted ]]
[[ rowChartData.lowPrice ]]
[[ rowChartData.labelHigh ]]
[[ rowChartData.highPriceFormatted ]]
[[ rowChartData.highPrice ]]
since [[ rowChartData.lowDate ]]
since [[ rowChartData.highDate ]]
[[ value ]] [[ value ]]
Realtime quote and/or trades are not sourced from all markets.

Fundamentals

See More
  • Market Capitalization, $K 590,939
  • Shares Outstanding, K 29,786
  • Annual Sales, $ 26,740 K
  • Annual Income, $ -58,330 K
  • 60-Month Beta 1.46
  • Price/Sales 13.40
  • Price/Cash Flow N/A
  • Price/Book 8.39
Trade CALT with:

Options Overview Details

View History
  • Implied Volatility 109.41% ( -0.51%)
  • Historical Volatility 63.83%
  • IV Percentile 70%
  • IV Rank 49.85%
  • IV High 173.46% on 10/21/22
  • IV Low 45.74% on 06/08/22
  • Put/Call Vol Ratio 0.00
  • Today's Volume 1
  • Volume Avg (30-Day) 3
  • Put/Call OI Ratio 0.53
  • Today's Open Interest 179
  • Open Int (30-Day) 458

Analyst Rating / Earnings Estimates

Current Rating
See More
Strong Buy
Based on 3 analysts offering recommendations.
Earnings Estimates - Current Qtr 12/31/22
See More
  • Average Estimate -0.47
  • Number of Estimates 2
  • High Estimate -0.42
  • Low Estimate -0.52
  • Prior Year -0.95
  • Growth Rate Est. (year over year) +50.53%

Price Performance

See More
Period Period Low Period High Performance
1-Month
17.08 +10.83%
on 01/05/23
21.00 -9.83%
on 01/18/23
+1.93 (+11.38%)
since 12/30/22
3-Month
13.30 +42.37%
on 11/02/22
21.00 -9.83%
on 01/18/23
+4.43 (+30.59%)
since 10/28/22
52-Week
10.82 +75.00%
on 10/20/22
23.01 -17.71%
on 02/09/22
-0.82 (-4.13%)
since 01/28/22

Most Recent Stories

More News
New Strong Sell Stocks for January 6th

CALT, CVGW and DFH have been added to the Zacks Rank #5 (Strong Sell) List on January 6, 2023.

CVGW : 31.64 (-0.25%)
CALT : 18.93 (-4.56%)
DFH : 11.70 (+4.46%)
Calliditas CEO acquires shares through the exercise of Calliditas' warrant program 2019/2022

/PRNewswire/ -- Calliditas Therapeutics AB (publ) (Nasdaq: CALT, Nasdaq Stockholm: CALTX) ("Calliditas") announced today that CEO Renée Aguiar-Lucander has net...

CALT : 18.93 (-4.56%)
Calliditas Therapeutics announces license agreement with Viatris to register and commercialize specialty therapy for IgA nephropathy in Japan

/PRNewswire/ -- Calliditas Therapeutics AB (NASDAQ: CALT) (NASDAQ Stockholm: CALTX) ("Calliditas") announced today that they have entered into an exclusive...

CALT : 18.93 (-4.56%)
VTRS : 11.94 (+0.42%)
Calliditas' partner Everest Medicine's New Drug Application for Nefecon is accepted by the China NMPA

/PRNewswire/ -- Calliditas Therapeutics AB (Nasdaq: CALT) (Nasdaq Stockholm: CALTX) ("Calliditas") today announced that the Chinese regulatory authority...

CALT : 18.93 (-4.56%)
Aurinia (AUPH) Moves 13.1% Higher: Will This Strength Last?

Aurinia (AUPH) saw its shares surge in the last session with trading volume being higher than average. The latest trend in earnings estimate revisions may not translate into further price increase in the...

AUPH : 8.94 (-4.59%)
CALT : 18.93 (-4.56%)
Kidney International Publishes Results from NefIgArd Phase 3 Trial Evaluating TARPEYO® (budesonide) in IgA Nephropathy

/PRNewswire/ -- Calliditas Therapeutics AB (Nasdaq: CALT) (Nasdaq Stockholm: CALTX) ("Calliditas") today announced Kidney International has published the...

CALT : 18.93 (-4.56%)
Can Calliditas Therapeutics AB Sponsored ADR (CALT) Climb 160% to Reach the Level Wall Street Analysts Expect?

The average of price targets set by Wall Street analysts indicates a potential upside of 160.3% in Calliditas Therapeutics AB Sponsored ADR (CALT). While the effectiveness of this highly sought-after metric...

CALT : 18.93 (-4.56%)
How Much Upside is Left in Calliditas Therapeutics AB Sponsored ADR (CALT)? Wall Street Analysts Think 200%

The consensus price target hints at a 200.3% upside potential for Calliditas Therapeutics AB Sponsored ADR (CALT). While empirical research shows that this sought-after metric is hardly effective, an upward...

CALT : 18.93 (-4.56%)
Everest Medicines Announces European Commission Grants Approval of Kinpeygo® for Adults with Primary IgA Nephropathy to our Partner Calliditas Therapeutics

/PRNewswire/ -- Everest Medicines (HKEX 1952.HK, "Everest", or the "Company"), announced today that our partner Calliditas Therapeutics AB (Nasdaq: CALT,...

CALT : 18.93 (-4.56%)
European Commission approves Kinpeygo® for adults with primary IgA nephropathy

/PRNewswire/ -- Calliditas Therapeutics AB (Nasdaq: CALT, Nasdaq Stockholm: CALTX) ("Calliditas") today announced that the European Commission (EC) has granted...

CALT : 18.93 (-4.56%)

Barchart Technical Opinion

The Barchart Technical Opinion rating is a 72% Buy with a Average short term outlook on maintaining the current direction.

See More Share

Business Summary

Calliditas Therapeutics AB is a specialty pharmaceutical company. It is focused on developing pharmaceutical products for patients with a significant unmet medical need. The compnay's lead candidate consist Nefecon. Calliditas Therapeutics AB is based in Stockholm, Sweden.

See More

Key Turning Points

3rd Resistance Point 19.74
2nd Resistance Point 19.44
1st Resistance Point 19.19
Last Price 18.93
1st Support Level 18.64
2nd Support Level 18.35
3rd Support Level 18.09

See More

52-Week High 23.01
Last Price 18.93
Fibonacci 61.8% 18.35
Fibonacci 50% 16.92
Fibonacci 38.2% 15.48
52-Week Low 10.82

See More

Want to use this as
your default charts setting?
Save this setup as a Chart Templates
Switch the Market flag
for targeted data from your country of choice.
Open the menu and switch the
Market flag for targeted data from your country of choice.
Want Streaming Chart Updates?
Switch your Site Preferences
to use Interactive Charts
Need More Chart Options?
Right-click on the chart to open the Interactive Chart menu.

Free Barchart Webinar